Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart Failure (HF) significantly contributes to global morbidity and mortality, imposing a substantial economic burden.
• Standard treatments like ACEIs, ARBs, BBs, and MRAs are effective but HF prevalence continues to rise.
• Existing therapies have limitations despite proven efficacy and cost-effectiveness.

Purpose of the Study:

• To review current guideline-approved indications for Sacubitril/Valsartan (SAC/VAL) in HF management.
• To highlight potential emerging indications for SAC/VAL.
• To discuss ongoing clinical trials investigating expanded uses of SAC/VAL.

Main Methods:

• Literature review of current guidelines and clinical trial data.
• Analysis of recent research on Sacubitril/Valsartan (SAC/VAL) efficacy and safety.
• Discussion of the role of Angiotensin Receptor/Neprilysin Inhibitors (ARNIs) in HF treatment.

Main Results:

• Sacubitril/Valsartan (SAC/VAL) demonstrates superior efficacy in improving quality of life and reducing adverse events in HFrEF patients compared to traditional therapies.
• SAC/VAL is now recommended as an alternative to ACEIs or ARBs for reducing morbidity and mortality in HFrEF.
• Emerging data suggests potential benefits in broader HF populations.

Conclusions:

• Sacubitril/Valsartan (SAC/VAL) represents a significant advancement in HFrEF treatment, offering improved patient outcomes.
• Further research and ongoing trials are expected to expand the therapeutic role of SAC/VAL in various HF contexts.
• The integration of ARNIs like SAC/VAL into HF guidelines marks a shift towards more effective therapeutic strategies.